A Phase 2 interventional study of Tibulizumab and Placebo in Systemic Sclerosis (SSc) and Scleroderma, sponsored by Zura Bio Inc. Active, not recruiting at 60 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Zura Bio Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Scleroderma, Systemic with a site in Argentina — 4 open to participants now, 6 under way, 3 of them phase 3. Scleroderma, Systemic · Argentina.
Among the 14 studies in Scleroderma, Systemic with a site in Argentina, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 2, and was the 12th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →4 of the 14 studies in Scleroderma, Systemic with a site in Argentina are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Argentina, United States, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in Argentina, United States, Australia and 42 more countries
Ages 18+
GlaxoSmithKline · Sites in Argentina, United States, Australia and 15 more countries
Ages 18+
EPIMAR registry · Sites in Argentina
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5
First in 2015; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 174 across the 13 interventional studies, 1,000 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 10 most frequent:
Zura Bio Inc is the lead sponsor of 2 studies on the registry; none are open to participants now.
Zura Bio Inc has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
2 of the studies in Scleroderma, Systemic with a site in Argentina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Scleroderma, Systemic with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has any of the following complications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection
Biological: Tibulizumab
Subcutaneous injection
Biological: Tibulizumab · Other: Placebo
Anti BAFF/IL-17 antibody
Also known as: ZB-106
Placebo (inactive)
Also known as: ZB-106 placebo
[Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks
The mRSS assesses skin thickness at 17 different cutaneous sites across the body using a scale from 0 (normal skin) to 3 (severe thickening), with a total score ranging from 0 (no thickening) to 51 (severe thickening in all 17 areas)
Time frame: Week 24
[Period 2] Safety and tolerability of tibulizumab
Assessed by the incidence of all treatment-emergent adverse events (TEAEs), as well as changes from baseline in vital signs, electrocardiogram (ECG) parameters, and laboratory results
Time frame: Week 52
[Period 1] Change from baseline in quantitative interstitial lung disease (QILD) obtained with high-resolution quantitative tomography (HRCT) in the whole lung in participants with SSc-interstitial lung disease (ILD)
HRCT measures the extent of interstitial lung disease by quantifying the amount of lung fibrosis, ground-glass opacity, and honeycomb lung, which are used to calculate the QILD score (scores can range from 0 to 100%, with higher scores indicating greater disease extent)
Time frame: Week 24
[Period 1] Change from baseline in forced vital capacity (FVC) in participants with SSc-ILD
FVC is the amount of air that can be forcibly exhaled after the deepest possible breath
Time frame: Week 24
[Period 1] Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
HAQ-DI evaluates patients' self-assessed degree of disability across eight categories, with scores ranging from 0 to 3, where 3 indicates the worst degree of disability
Time frame: Week 24
[Period 1] Safety and tolerability of tibulizumab
Assessed by the incidence of all TEAEs, as well as changes from baseline in vital signs, ECG parameters, and laboratory results
Time frame: Week 24
[Period 2] Change from baseline in mRSS
The mRSS assesses skin thickness at 17 different cutaneous sites across the body using a scale from 0 (normal skin) to 3 (severe thickening), with a total score ranging from 0 (no thickening) to 51 (severe thickening in all 17 areas)
Time frame: Week 52
[Period 2] Change from baseline in QILD obtained with HRCT in the whole lung in participants with SSc-ILD
HRCT measures the extent of interstitial lung disease by quantifying the amount of lung fibrosis, ground-glass opacity, and honeycomb lung, which are used to calculate the QILD score (scores can range from 0 to 100%, with higher scores indicating greater disease extent)
Time frame: Week 52
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tibulizumab
Zura Bio Inc